2025-05-28 - Analysis Report
Okay, here's the analysis of Recursion Pharmaceuticals Inc. (RXRX) based on the data you provided, presented in an easy-to-understand format with a focus on the key takeaways.

## RXRX Stock Analysis (as of May 28, 2024)

**Company Overview:** Recursion Pharmaceuticals Inc. is a clinical-stage biotechnology company leveraging artificial intelligence to discover, develop, and commercialize novel therapeutics.

### 1. Performance vs. S&P 500 (VOO)

*   **RXRX Cumulative Return:** -61.23%
*   **VOO Cumulative Return:** 15.99%
*   **Absolute Divergence (Current):** -77.2%
*   **Relative Divergence:** 0.0

**Analysis:** RXRX has significantly underperformed the S&P 500. The current divergence is at the lowest end of its historical range, suggesting extreme underperformance relative to the market benchmark.

**Alpha, Beta Analysis Table:**

| Year       | CAGR   | MDD    | Alpha    | Beta   | Cap(B) |
| :----------- | :----- | :----- | :------- | :----- | :----- |
| 2021-2023  | 5.0%   | 73.6%  | 1.0%     | -0.1   | 4.0    |
| 2022-2024  | 0.0%   | 73.6%  | -17.0%    | -0.1   | 2.8    |
| 2023-2025  | -10.0%  | 75.5%  | -41.0%    | -0.1   | 1.8    |

**Analysis:**

*   **CAGR Trend:** The Compound Annual Growth Rate (CAGR) is declining over the periods analyzed, indicating weakening growth.
*   **MDD:** The Maximum Drawdown (MDD) remains very high, indicating significant risk and price volatility.
*   **Alpha:** The Alpha is negative, suggesting that the stock is underperforming its benchmark on a risk-adjusted basis.
*   **Beta:** The negative Beta implies that the stock moves inversely to the market, which is unusual.
*   **Cap(B):** The market capitalization is decreasing, indicating that the company's size is shrinking.

### 2. Recent Price Action

*   **Current Price:** $4.39
*   **Previous Close:** $4.08
*   **Change:** 7.6%
*   **5-day Moving Average:** 4.252
*   **20-day Moving Average:** 4.6185
*   **60-day Moving Average:** 5.3909

**Analysis:** The stock saw a positive change recently (7.6% increase). The price is currently above the 5-day moving average but below the 20-day and 60-day moving averages, suggesting a possible short-term upward trend but longer-term downward momentum.

### 3. Market Risk Indicators and Return Expectation

*   **Market Risk Indicator (MRI):** 0.366 (Low Risk)
*   **RSI:** 55.16
*   **PPO:** -0.0685
*   **Hybrid Signal:** cash_70%_Sell 69.9% of holdings (3323 shares - Caution - MRI:0.37)
*   **Recent (20-day) Relative Divergence Change:** -1.0 (downward trend)
*   **Expected Return:** -2421.4%

**Analysis:**

*   **MRI:** The MRI indicates low risk.
*   **RSI:** The RSI is around 55, suggesting neutral momentum.
*   **PPO:** The negative PPO suggests that the short-term moving average is below the long-term moving average, indicating a downward trend.
*   **Hybrid Signal:** The signal suggests a cautious approach, advising to hold a significant cash position (70%) and sell a considerable portion of holdings.
*   **Recent Price Change Reflection:** The significant price change (7.6%) suggests a recent positive event.
*   **Expected Return:** The extremely negative expected return suggests significant challenges and high uncertainty about the stock's future performance.

### 4. Recent News & Significant Events

*   **Volatility:** The stock has shown notable volatility.
*   **Analyst Discussions:** Analysts are discussing the company's performance in the context of industry trends and global economic factors.
*   **Business Developments:** The company has recently made headlines due to major business developments, regulatory changes, or market events.
*   **Expert Advice:** Market experts highlight both risks and opportunities and advise monitoring recent news.

**Analysis:** Recent news suggests that the company is undergoing significant changes and is subject to market volatility, indicating that investors should closely monitor developments.

### 5. Recent Earnings Analysis:

| Date       | EPS    | Revenue  |
| :---------- | :----- | :------- |
| 2025-05-05 | -0.5   | 0.01 B$  |
| 2024-11-06 | -0.34  | 0.03 B$  |
| 2024-08-08 | -0.4   | 0.01 B$  |
| 2024-05-09 | -0.39  | 0.01 B$  |
| 2025-05-05 | -0.39  | 0.01 B$  |

**Analysis:** The company has consistently reported negative EPS. Revenue has been fluctuating but generally remains low.

### 6. Financial Information

**Revenue and Profitability:**

| Quarter    | Revenue   | Profit Margin |
| :--------- | :-------- | :------------ |
| 2025-03-31 | $0.01B    | -47.31%       |
| 2024-12-31 | $0.00B    | -183.62%      |
| 2024-09-30 | $0.03B    | 53.69%        |
| 2024-06-30 | $0.01B    | 36.14%        |
| 2024-03-31 | $0.01B    | 17.23%        |

**Capital and Profitability:**

| Quarter    | Equity    | ROE       |
| :--------- | :-------- | :-------- |
| 2025-03-31 | $0.93B    | -21.68%   |
| 2024-12-31 | $1.03B    | -17.29%   |
| 2024-09-30 | $0.52B    | -18.27%   |
| 2024-06-30 | $0.58B    | -16.69%   |
| 2024-03-31 | $0.40B    | -22.78%   |

**Analysis:**

*   **Revenue:** Revenue is inconsistent, with one quarter showing a significant spike.
*   **Profit Margin:** The company's profit margins are volatile, with some quarters showing substantial losses.
*   **Equity:** Equity has fluctuated but remains relatively high.
*   **ROE:** Return on Equity (ROE) is consistently negative, indicating poor profitability.

### 7. Overall Summary

RXRX has significantly underperformed the S&P 500. While there has been a recent positive price movement, the overall picture suggests a struggling company with negative profitability, high volatility, and a very negative expected return. The hybrid signal recommends caution and a high cash position. Recent news indicates that the company is undergoing significant changes and market events, suggesting that investors should closely monitor developments.

**Recommendation:** Given the current data, a conservative approach is warranted. Holding a substantial cash position and closely monitoring company announcements and news would be prudent. The data suggests this investment carries a high degree of risk.
